Skip to content
ATLAS PREP HQ
Fat Loss

Retatrutide

LY3437943, a single-molecule GLP-1/GIP/glucagon triple receptor agonist

Triple GLP-1, GIP, and glucagon receptor agonist research focused on obesity and metabolic outcomes.

Strong Human Evidence

Route

Subcutaneous.

Common format

10 mg vial

Research focus

obesity

Evidence level

Strong Human Evidence

Typical cycle

36–48+ weeks (trials)

Fat Loss research motifFat Loss

Retatrutide in 30 seconds

Atlas Fast Read

What it is

LY3437943, a single-molecule GLP-1/GIP/glucagon triple receptor agonist

Why people care

Triple GLP-1, GIP, and glucagon receptor agonist research focused on obesity and metabolic outcomes.

Human evidence

Strong Human Evidence — Substantial randomized or late-phase human evidence with clinically meaningful outcomes, and/or well-established clinical use relevant to the stated claim.

Biggest misconception

Long-term cardiovascular outcomes, durability after discontinuation, optimal maintenance, body-composition quality, tolerability at higher doses, and final approved indications/dosing remain important while development continues.

Bottom line

Retatrutide is not speculative in the way many gray-market peptides are: large human trials show powerful weight-loss and metabolic effects.

Overview

What is Retatrutide?

Retatrutide is lY3437943, a single-molecule GLP-1/GIP/glucagon triple receptor agonist. Triple GLP-1, GIP, and glucagon receptor agonist research focused on obesity and metabolic outcomes.

Retatrutide was developed by Eli Lilly as a single triple agonist targeting GLP-1, GIP, and glucagon receptors. Preclinical work appeared in 2022 and major phase 2 obesity and diabetes results followed in 2023; it remains investigational as of August 2026.

Mechanism

How it works

Agonizes GLP-1, GIP, and glucagon receptors in one molecule. GLP-1/GIP reduce appetite and improve insulin-related physiology, while glucagon-receptor activity may increase energy expenditure and hepatic lipid mobilization.

Research areas

obesitytype 2 diabetesfatty liver/metabolic diseaseenergy expenditure

Evidence

What does the evidence actually say?

Strong Human Evidence

Substantial randomized or late-phase human evidence with clinically meaningful outcomes, and/or well-established clinical use relevant to the stated claim.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Retatrutide has strong phase 2 and late-stage human clinical evidence showing large reductions in body weight and improvements in metabolic outcomes. It remains investigational as of August 2026, so trial dosing and safety monitoring should not be confused with an approved prescribing label.

Preclinical evidence

Rodent and primate studies supported simultaneous GLP-1/GIP/glucagon agonism, weight loss, and metabolic improvements, enabling human clinical development. Human trials now provide the stronger evidence.

Knowledge gaps

Long-term cardiovascular outcomes, durability after discontinuation, optimal maintenance, body-composition quality, tolerability at higher doses, and final approved indications/dosing remain important while development continues.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Phase 2/3 development has studied weekly doses across roughly 1–12 mg with stepwise titration. Community reference: 2 → 4 → 6 → 8 mg weekly, with higher 12 mg trial doses described elsewhere.

Frequency

Once weekly.

Timing

Same day each week; exact clock time is not critical.

Route

Subcutaneous.

Cycle length

36–48+ weeks (trials)

Reconstitution

Community research-vial reference: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized at -20 °C; reconstituted 2–8 °C for up to about 4 weeks.

Monitoring

Weight/waist, BP, glucose/HbA1c, renal/hepatic function as indicated, lipids, nutrition/hydration and GI adverse effects; monitor for pancreatitis/gallbladder symptoms and excessive lean-mass loss.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Most common effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort, reduced appetite and reflux. Clinically important risks can include dehydration/acute kidney injury, gallbladder disease and pancreatitis; rapid weight loss can contribute to lean-mass loss.

Contraindications

Retatrutide remains investigational, so there is no final approved contraindication label. Trial exclusion criteria and class concerns include pregnancy, significant GI disease, pancreatitis risk, serious endocrine disease and hypersensitivity.

Interactions

Slower gastric emptying can change absorption/timing of oral medicines. When combined with insulin or insulin secretagogues, hypoglycemia risk can rise; dose adjustment belongs under medical supervision. Do not combine overlapping incretin therapies unless specifically studied/prescribed.

Stacks

Common stacks

Retatrutide alone

Because retatrutide already targets GLP-1, GIP and glucagon receptors, stacking it with other incretin agonists adds overlapping pharmacology and is not an evidence-based default.

Avoid treating overlapping incretin combinations as established or safe.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Retatrutide is not speculative in the way many gray-market peptides are: large human trials show powerful weight-loss and metabolic effects. The key caution is status—while investigational, trial protocols are not the same thing as an approved prescription, and long-term positioning is still evolving.

More in Fat Loss

Fat Loss

5-Amino-1MQ

Selective NNMT-inhibitor research focused on cellular energy balance and metabolic function.

Read guide

Fat Loss

AOD-9604

Modified growth-hormone fragment studied for lipolysis and fat-metabolism effects without targeting IGF-1.

Read guide

Fat Loss

Cagrilintide

Long-acting amylin-analog research focused on appetite regulation, satiety, and body-weight reduction.

Read guide